• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Radiotherapy and chemotherapy in invasive bladder cancer with potential bladder sparing.

作者信息

Kaufman D S, Shipley W U, Althausen A F

机构信息

Medical Oncology Service, Massachusetts General Hospital Cancer Center, Boston.

出版信息

Hematol Oncol Clin North Am. 1992 Feb;6(1):179-94.

PMID:1556049
Abstract

The standard treatment in the United States for patients with muscle infiltrating tumors is radical cystectomy with or without radiation treatment. The results of such treatment have been generally unsatisfactory, with 40% or more patients developing systemic disease with a 5-year survival rate of less than 50%. Combination chemotherapy employing both cisplatin and methotrexate can produce a 30% to 50% clinical complete response rate (negative biopsy, negative urinary cytology) of the primary tumor. Although the optimal combination of chemotherapeutic agents has not yet been determined, it is unlikely that combination chemotherapy alone, even in completely responding patients, will be adequate to rid the bladder of a primary invasive transitional cell carcinoma. Additional therapy by either surgery or external beam radiotherapy seems warranted owing to the high likelihood that there will be residual microscopic tumor in the bladder. Concomitant systemic chemotherapy and external beam radiotherapy produces complete remissions in 65% to 90% of patients. Follow-up of from 3 to 5 years following full chemoradiotherapy will be necessary to be certain that the bladder has been sterilized of cancer. Combined cisplatin and external beam radiation (using a boost technique that spares the section of the bladder uninvolved with tumor) does not seem to enhance local soft-tissue toxicity (relative to the radiotherapy alone) with the exception of the neurotoxicity seen with intra-arterial cisplatin. Debulking TURB tumor appears to improve the local success rate for patients being considered for bladder preservation with the use of the combination of systemic chemotherapy and/or radiotherapy. Not all patients respond to concomitant chemotherapy and radiation therapy. Our current approach is that the selection process must be carried on at several points during the treatment. Only patients who respond completely to the initial courses of chemotherapy and radiation should be carried to a full radiation dose. In the absence of a complete response following upfront chemotherapy and 4000 cGy in combination with additional cisplatin courses, cystectomy at that point is the recommended treatment.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

相似文献

1
Radiotherapy and chemotherapy in invasive bladder cancer with potential bladder sparing.
Hematol Oncol Clin North Am. 1992 Feb;6(1):179-94.
2
Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.经尿道切除术、长期静脉输注化疗及超分割放疗对浸润性膀胱癌的保守治疗:长期结果
Cancer. 2004 Dec 1;101(11):2540-8. doi: 10.1002/cncr.20654.
3
Can patient selection for bladder preservation be based on response to chemotherapy?保膀胱治疗的患者选择能否基于化疗反应?
Cancer. 2003 Apr 1;97(7):1644-52. doi: 10.1002/cncr.11232.
4
Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.接受保守多模式治疗的局部晚期膀胱癌患者的临床结局
Urology. 2004 Sep;64(3):488-93. doi: 10.1016/j.urology.2004.04.088.
5
Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.质子束疗法治疗浸润性膀胱癌:一项联合放疗和动脉内化疗的保膀胱治疗前瞻性研究。
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1371-9. doi: 10.1016/j.ijrobp.2005.10.023.
6
Predictive factors for outcome in invasive bladder cancer treated with alternating chemoradiotherapy.交替放化疗治疗浸润性膀胱癌预后的预测因素
Cancer J Sci Am. 1997 Jul-Aug;3(4):213-23.
7
[Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].[顺铂与同期放疗对无法手术切除的膀胱癌进行长期治疗的结果:局部控制和生存的预后因素]
Cancer Radiother. 1998 Apr;2 Suppl 1:85s-91s.
8
A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.一项针对可手术切除的肌层浸润性膀胱癌患者的I/II期试验,采用经尿道手术联合顺铂、5-氟尿嘧啶同步化疗及每日两次放疗,随后进行选择性膀胱保留。
J Urol. 1998 Nov;160(5):1673-7.
9
Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy.对于不适合进行根治性膀胱切除术的肌肉浸润性膀胱癌患者,采用顺铂与放疗同步治疗。
J Urol. 1996 Oct;156(4):1258-62.
10
Overview of bladder cancer trials in the Radiation Therapy Oncology Group.放射肿瘤学组膀胱癌试验概述
Cancer. 2003 Apr 15;97(8 Suppl):2115-9. doi: 10.1002/cncr.11282.

引用本文的文献

1
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.肌肉浸润性膀胱癌的膀胱保留治疗方法
Curr Treat Options Oncol. 2016 Mar;17(3):15. doi: 10.1007/s11864-016-0390-8.
2
The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification.肿瘤扩散、分级及生长模式作为膀胱癌形态学预测参数的价值。对1987年TNM分类的批判性修订。
J Cancer Res Clin Oncol. 1993;119(10):578-93. doi: 10.1007/BF01372721.